Kraig Biocraft Laboratories, Inc. KBLB
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Kraig Biocraft Laboratories, Inc. is a biotechnology materials company focused on the development and commercialization of genetically engineered spider silk fibers and advanced recombinant silk technologies. The company operates primarily in the biomaterials and performance textiles industries, using genetic engineering techniques to produce silk fibers with characteristics associated with natural spider silk, including high tensile strength, elasticity, and lightweight performance. Kraig Biocraft Laboratories generates value through the research, development, production, and anticipated commercialization of proprietary silk-based materials intended for technical textiles, defense applications, medical materials, and specialty apparel markets.
The company’s principal business activities center on engineered silkworm strains designed to produce recombinant spider silk proteins during the silk-spinning process. Its proprietary technologies and product platforms include variants marketed under names such as Dragon Silk, Monster Silk, and other recombinant silk lines. Kraig Biocraft Laboratories was founded in 2006 and is headquartered in the United States. Over time, the company evolved from an early-stage biotechnology research organization into a commercialization-focused enterprise emphasizing scaled silk production, international manufacturing partnerships, and intellectual property development related to transgenic silk technologies.
Business Operations
Kraig Biocraft Laboratories conducts operations through biotechnology research, silkworm genetics development, silk production management, and commercialization initiatives. The company’s business model is based on creating proprietary transgenic silkworm strains capable of producing high-performance silk fibers at commercial scale. Revenue generation has historically been limited relative to larger industrial biotechnology firms, with operations focused heavily on research and development, pilot production, and strategic commercialization activities. Public disclosures indicate that the company has pursued manufacturing and operational relationships in Southeast Asia, particularly through silk production activities in Vietnam.
The company controls intellectual property associated with recombinant spider silk production technologies and engineered silkworm breeding platforms. Its operations include collaboration with government agencies, textile manufacturers, and commercial development partners aimed at scaling silk output and evaluating industrial applications. Kraig Biocraft Laboratories has also referenced partnerships and production arrangements connected to silk rearing, textile processing, and downstream material integration. Data regarding the long-term commercial scale and profitability of these arrangements remains limited based on available public disclosures.
Strategic Position & Investments
Kraig Biocraft Laboratories’ strategic direction centers on transitioning from developmental biotechnology research into scaled commercial production of recombinant spider silk materials. The company has emphasized increasing silk output capacity, expanding silkworm breeding programs, improving production consistency, and securing commercial relationships for technical textile applications. Strategic initiatives have included investments in production infrastructure, expanded operational capabilities in Asia, and continued refinement of proprietary transgenic silkworm lines designed to improve fiber performance and manufacturing efficiency.
The company has also positioned itself within emerging advanced materials and biomimetic manufacturing sectors, where lightweight high-strength fibers are viewed as potentially valuable across defense, aerospace, medical, and performance apparel applications. Kraig Biocraft Laboratories has publicly discussed opportunities tied to military-grade textiles and specialty fabrics. While the company has announced various commercialization milestones and production targets, some future production scale expectations and market adoption timelines remain subject to execution risk and have not yet been fully validated through large-scale recurring commercial revenue.
Geographic Footprint
Kraig Biocraft Laboratories is headquartered in Michigan, United States, while maintaining operational and production activities tied to Vietnam and broader Southeast Asia. The company’s international footprint is closely linked to silk cultivation and manufacturing partnerships in regions with established sericulture infrastructure. Vietnam has been identified in company disclosures as a key operational center for silkworm breeding, cocoon production, and silk processing initiatives.
The company’s market ambitions are global in scope, with intended commercial applications spanning North America, Asia, and potentially Europe through technical textile and specialty materials markets. Its international strategy relies on combining U.S.-based biotechnology and intellectual property development with lower-cost silk production ecosystems overseas. Publicly available information indicates that the company continues to prioritize expansion of production capabilities in Asia as part of its commercialization efforts.
Leadership & Governance
Kraig Biocraft Laboratories was founded by Kim Thompson, who has played a central role in shaping the company’s biotechnology strategy and commercialization direction. Leadership communications have consistently emphasized the goal of establishing scalable recombinant spider silk manufacturing using genetically engineered silkworms rather than synthetic polymer alternatives. The company’s governance approach reflects a focus on intellectual property development, production scale-up, and strategic commercialization partnerships within advanced materials markets.
Key executives and leadership figures include:
- Kim Thompson – Founder and Chief Executive Officer
- Jon Rice – Chief Operating Officer
Additional executive and governance information beyond publicly disclosed leadership roles is limited in some filings and corporate materials. Data inconclusive based on available public sources regarding broader executive team composition and long-term governance structure changes.